Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
RIXPHARMA from Rixensart, company number BE0882172240, closed financial year 2025 with a result of € -5,655 after tax. For that financial year RIXPHARMA recorded a gross margin of € -5,255 and equity of € 107,377. Compared with financial year 2024, the result moved from € -3,643 to € -5,655. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.
€ 107,377
▼ 5% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5,655
▼ 55 % more loss than in 2024
Profit after tax over the fiscal year.
€ 114,500
▼ 68% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 11,177.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 792
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 8,082 | € 8,254 | € -3,256 | € -5,255 | ▼ € 1,999 |
| Profit after taxes | € -4,213 | € 7,253 | € -3,643 | € -5,655 | ▼ € 2,012 |
| Equity | € 109,422 | € 116,676 | € 113,032 | € 107,377 | ▼ 5% |
| Total debts | € 83,874 | € 312,427 | € 244,887 | € 45,679 | ▼ 81% |
| Cash | € 153,930 | € 428,671 | € 357,920 | € 114,500 | ▼ 68% |
| Land & buildings | € 36,485 | - | - | - | |
| Retained profit | € 13,222 | € 20,476 | € 16,832 | € 11,177 | ▼ 34% |
| Balance sheet total | € 193,296 | € 429,103 | € 357,920 | € 153,057 | ▼ 57% |
Key figures of RIXPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about RIXPHARMA the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to RIXPHARMA?
What happened at RIXPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 5,655. filed late Source: NBB ↗
- New establishment in Rixensart. KBO
- Incorporation, published in the Gazette. Source: Staatsblad ↗
In short
From € 4,213 loss in 2022 to € 5,655 loss in 2025.
Best year ever: 2023, with € 7,253 profit.
Management
Behind RIXPHARMA is Thibault Bataille.
Directors
According to the 2025 annual accounts
Thibault Bataille
Director
Establishments
Establishment units
Physical locations of this company
Avenue John Kennedy 45
1330 Rixensart
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- BATAILLE Thibault Pierre Jean(oprichter) 99%
- VANDERBECKEN Isabelle Lucie Georgette(oprichter) 1%
Details
- Company number
- 0882.172.240
- VAT number
- BE 0882.172.240
- Registered office
- Avenue John Kennedy 45, 1330 Rixensart
- Names & denominations
- RIXPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 June 2006
- Peppol
- Active · Active since 3 Mar 2026